History of acib
Austria has a long tradition in industrial biotechnology – particularly Vienna and Graz have established themselves as centres of biotech research. Graz University of Technology and the University for Natural Ressources and Life Sciences in Vienna are well-known for their work in industrial biotechnology. In Graz the efforts led to the formation of the Research Centre Applied Biocatalysis (A-B), in Vienna the Austrian Center of Biopharmaceutical Biotechnology (ACBT) was founded as a pioneering research organization.
As well A-B as ACBT can look back at very successful work during the past years. The scientific orientation of the research work led to about 500 scientific publications, the application-oriented one to about 20 patents and patent applications. ACBT succeeded in the development of new technologies for a more efficient production of recombinant pharma-proteins with bacterial and mammalian cell expression systems. Five processes for industrial biocatalytic production developed by A-B have already been implemented by our industrial partners up to multi-ton scale.
Outstanding examples for the development of both centres are for instance the autoprotease-fusion protein-technology for the expression of new and high-quality biopharmaceutical agents in E.coli and the enantiomerically pure intermediates for ACE-inhibitors and an antiplatelet drug which ranks among the top-ten of pharmaceuticals. Furthermore, the successful work was honored with a series of scientific awards such as the well renowned Dr. Wolfgang Houska Award of the B&C Private Foundation remunerated with €100.000.
In 2008 the two successful research centres decided to join forces and build up a joint research centre. They applied for a K2 research centre in the framework of the Austrian COMET programme. After a positive evaluation procedure an international jury suggested acib for funding as a K2 centre.
The new centre started its work on January 1, 2010 and was officially renamed into acib Gmbh.